1,3,5-Tri-O-benzoyl-D-Ribofuranose CAS 22224-41-5 Puritas ≥99.0% Clofarabine Intermedia Alta Puritas Featured Image

1,3,5-Tri-O-benzoyl-D-Ribofuranose CAS 22224-41-5 Puritas ≥99.0% Clofarabine Intermedia High Munditia

Description:

Nomen chemicum: 1,3,5-Tri-O-benzoyl-D-Ribofuranose

CAS: 22224-41-5

Aspectus: Alba vel Off-White pulveris

Puritas: ≥99.0%

Intermedia Clofarabine (CAS: 123318-82-1) in tractatione Puerorum cum Leukemia acuta Lymphoblastica (ALL)

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Commercial Supple Clofarabine Intermedia:
Clofarabine CAS: 123318-82-1
2-Deoxy-2-fluoro-1,3,5-tri-O-benzoyl-α-D-arabinofuranose CAS: 97614-43-2
β-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate CAS: 6974-32-9
1,3,5-Tri-O-benzoyl-D-Ribofuranose CAS: 22224-41-5
2,6-Dichloropurinum CAS: 5451-40-1

Chemical Properties:

Nomen chemicum	1,3,5-Tri-O-benzoyl-D-Ribofuranose
CAS Number	22224-41-5
CATTUS Number	RF-PI223
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C26H22O8
M. Pondus	462.45
Liquescens punctum	125.0-129.0℃(lit.)
Solubilitas	Insolubilis in aqua
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba vel Off-White pulveris
Puritas	≥99.0%
Damnum in Siccatio	≤1.00%
Maximum Impuritas	≤0.50%
Totalis immunditias	≤1.00%
Metalla gravis	≤20ppm
Test Standard	Enterprise Standard
Consuetudinem	Medium Clofarabine (CAS: 123318-82-1)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, umore et peste infestatione.

commoda:

FAQ:

Applicatio:

1,3,5-Tri-O-benzoyl-D-Ribofuranose (CAS: 22224-41-5) initium est materia synthesis nucleosidis.Intermedium adhiberi potest Clofarabine (CAS: 123318-82-1).Clofarabine nova est medicamenta purina nucleoside anticancerorum primum feliciter enucleata a Top10 biopharmaceutica societas Foederatarum Americae-Genzyme Corporation cum nominibus artis "Clofarabine".Die 28 mensis Decembris anno 2004 FDA semita ieiunium Clofarabinae approbavit ad applicationes ad pueros refractorio vel relapso leukemia lymphocytica acuta.Clofarabine commoda Fludarabinae et Cladribinae coniungit ad inhibendum tam DNA polymerasium quam acidum RIbonucleicum reductase.In praesenti est solum medicamentum aptum ad curationem infantiae leukemia.Studiis probaverunt efficaciam medicinalem altissimam esse, et tota responsio aegrotorum nulla responsio ad duo chemotherapia conventionalis 31%.Patientia autem bona est, nulla vagus adversis motus;Antitumor-spectrum lata potentia proprietates habet.